Systemic lupus erythematosus-associated PAH: Is targeting inflammation the key to success?

European Respiratory Review

Volumn 20, Issue 122, 2011, Pages 218-219

  Fois E ^a,b   Sitbon, O ^c,d,e  

^a DELAFONTAINE HOSPITAL   (France)

^b Hôpital Cochin ^*  (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BOSENTAN; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOKINE; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOCORTICOID; GROWTH FACTOR; IMMUNOGLOBULIN G; PHOSPHODIESTERASE V INHIBITOR; PHOSPHOLIPID ANTIBODY; PROSTANOID; RHEUMATOID FACTOR;

DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; MIXED CONNECTIVE TISSUE DISEASE; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; SCHISTOSOMIASIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOEMBOLISM;

HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SCLERODERMA, SYSTEMIC;

EID: 82555195595     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007111     Document Type: Editorial

References (16)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
2. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
4. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
5. Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011; 20: 277-286.
6. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
7. Foïs E, Le Guern V, Dupuy A, et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol 2010; 28: 836-841.
8. Torre O, Harari S. Pleural and pulmonary involvement in systemic lupus erythematosus. Presse Med 2011; 40: e41-e51.
9. Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
10. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285.
11. Quismorio FP, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13: 349-359.
12. Jaïs X, Launay D, Yaïci A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-531.
13. Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
14. Ribeiro JM, Lucas M, Victorino RM. Remission of precapillary pulmonary hypertension in systemic lupus erythematosus. J R Soc Med 2001; 94: 32-33.
15. Heresi GA, Minai OA. Lupus-associated pulmonary hypertension: longterm response to vasoactive therapy. Respir Med 2007; 101: 2099-2107.
16. Degano B, Yaïci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009; 33: 92-98.